Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort.
Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, Gautschi O, Aboubakar F, Muñoz-Couselo E, Pierret T, Rothschild SI, Cortiula F, Reynolds KL, Thibault C, Gavralidis A, Blais N, Barlesi F, Planchard D, Besse BMD. Remon J, et al. Among authors: blais n. ESMO Open. 2024 May;9(5):103004. doi: 10.1016/j.esmoop.2024.103004. Epub 2024 Apr 22. ESMO Open. 2024. PMID: 38653155 Free PMC article.
Tele-refraction in tele-eye care settings.
Blais N, Tousignant B, Hanssens JM. Blais N, et al. Clin Exp Optom. 2022 Aug;105(6):573-581. doi: 10.1080/08164622.2021.2009736. Epub 2022 Jan 30. Clin Exp Optom. 2022. PMID: 35094668 Review.
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F, Routy B, Nassabein R, Belkaid W, Tran-Thanh D, Malo J, Tonneau M, Ouarzadi OE, Florescu M, Tehfe M, Blais N. Proulx-Rocray F, et al. Among authors: blais n. Cancer Treat Res Commun. 2023;37:100767. doi: 10.1016/j.ctarc.2023.100767. Epub 2023 Oct 10. Cancer Treat Res Commun. 2023. PMID: 37832364 Free article.
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R, Khoudigian S, Sharma A, On PV, Liu G. Rupp M, et al. Among authors: blais n. Curr Oncol. 2023 Jul 8;30(7):6559-6574. doi: 10.3390/curroncol30070481. Curr Oncol. 2023. PMID: 37504341 Free PMC article.
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK, Banerji SO, Blais N, Chu QS, Juergens RA, Leighl NB, Sacher A, Sheffield BS, Snow S, Vincent M, Wheatley-Price PF, Yip S, Melosky BL. Cheema PK, et al. Among authors: blais n. Curr Oncol. 2023 Jul 6;30(7):6473-6496. doi: 10.3390/curroncol30070476. Curr Oncol. 2023. PMID: 37504336 Free PMC article.
182 results